Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 9(s)-erythromycylamine
2. Erythromyclamine
3. Erythromyclamine, (9r)-isomer
4. Erythromyclamine, (9s)-isomer
1. Erythromycylamine
2. 26116-56-3
3. 9(s)-erythromycylamine
4. 9-epierythromycylamine
5. (9s)-erythromycyclamine
6. Brn 4241492
7. (9s)-erythromycylamine A
8. Erythromycin, 9-amino-9-deoxo-, (9s)-
9. Yx9kv1oma4
10. 9-amino-9-deoxoerythromycin
11. Chembl290242
12. Chebi:73708
13. Ly-24410
14. Epierythromycyl-a-amine
15. (3r,4s,5s,6r,7r,9r,10s,11s,12r,13s,14r)-10-amino-6-(((2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one
16. (9s)-9-amino-9-deoxyerythromycin
17. 9-amino-9-deoxo-erythromycin, Stereoisomer
18. (3r,4s,5s,6r,7r,9r,10s,11s,12r,13s,14r)-10-amino-6-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one
19. (9s)-9-deoxy-9-aminoerythromycin A
20. Unii-yx9kv1oma4
21. Erythromycin, 9-amino-9-deoxo-, Stereoisomer
22. Ec 406-790-7
23. Erythromycin, 9-amino-9-deoxo-, (9s)- (9ci)
24. Schembl13681694
25. Brl-42852er
26. Dtxsid00180750
27. Ex-a5468
28. Bdbm50417963
29. Mfcd00872156
30. Zinc94303289
31. Akos037651084
32. (3r,4s,5s,6r,7r,9r,10s,11s,12r,13s,14r)-10-amino-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
33. Ac-28327
34. Cs-15835
35. Ly-024410
36. Cs-0047729
37. D95598
38. J-016261
39. Q27144058
40. (3r,4s,5s,6r,7r,9r,10s,11s,12r,13s,14r)-10-amino-6-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-py
41. (3r,4s,5s,6r,7r,9r,10s,11s,12r,13s,14r)-10-amino-6-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one (non-preferred Name)
42. Ern
43. Ran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy
| Molecular Weight | 735.0 g/mol |
|---|---|
| Molecular Formula | C37H70N2O12 |
| XLogP3 | 3.5 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 7 |
| Exact Mass | 734.49287567 g/mol |
| Monoisotopic Mass | 734.49287567 g/mol |
| Topological Polar Surface Area | 203 Ų |
| Heavy Atom Count | 51 |
| Formal Charge | 0 |
| Complexity | 1140 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 19 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Erythromyclamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Erythromyclamine, including repackagers and relabelers. The FDA regulates Erythromyclamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Erythromyclamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Erythromyclamine supplier is an individual or a company that provides Erythromyclamine active pharmaceutical ingredient (API) or Erythromyclamine finished formulations upon request. The Erythromyclamine suppliers may include Erythromyclamine API manufacturers, exporters, distributors and traders.
click here to find a list of Erythromyclamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Erythromyclamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Erythromyclamine active pharmaceutical ingredient (API) in detail. Different forms of Erythromyclamine DMFs exist exist since differing nations have different regulations, such as Erythromyclamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Erythromyclamine DMF submitted to regulatory agencies in the US is known as a USDMF. Erythromyclamine USDMF includes data on Erythromyclamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Erythromyclamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Erythromyclamine suppliers with USDMF on PharmaCompass.
Erythromyclamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Erythromyclamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Erythromyclamine GMP manufacturer or Erythromyclamine GMP API supplier for your needs.
A Erythromyclamine CoA (Certificate of Analysis) is a formal document that attests to Erythromyclamine's compliance with Erythromyclamine specifications and serves as a tool for batch-level quality control.
Erythromyclamine CoA mostly includes findings from lab analyses of a specific batch. For each Erythromyclamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Erythromyclamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Erythromyclamine EP), Erythromyclamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Erythromyclamine USP).
LOOKING FOR A SUPPLIER?
